Triple-Photopeak Acquisition Improves Image Quality in Serial Post-Therapy [¹⁷⁷Lu]Lu-PSMA SPECT/CT (EANM 2026) - Sep 29, 2026 - Abstract #EP-0905; "Materials and A patient with metastatic prostate cancer undergoing treatment with lutetium (177Lu) vipivotide tetraxetan ([177Lu]Lu-PSMA-617) underwent quantitative post-therapy SPECT/CT at 4, 24, 72, and 144 hours following radiopharmaceutical administration... Triple-photopeak acquisition significantly improves both quantitative and qualitative image quality in serial post-therapy [177Lu]Lu-PSMA SPECT/CT, particularly during delayed low-count imaging. Optimized reconstruction further reduces image noise, although its effect on lesion detectability is less pronounced. Optimizing acquisition window selection and reconstruction strategy may improve the reliability of post-therapy dosimetry and lesion assessment."
Genito-urinary Cancer • Prostate Cancer • Solid Tumor
|
|
F. Farhadi 1; F. Massanes Basi 2; A. Ramirez 1; M. Morris 1; M. Ghesani 1; E. Siegel 1; H. Vija 2; B. Saboury 1
|